Drug Trial Radar · NCT04742634
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
209
Planned (sponsor's estimate)
Start
May 12, 2022
Primary completion
Nov 30, 2033
Study completion Nov 30, 2033
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Taiho Oncology, Inc.
- First posted
- Feb 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will perform ultra-deep, error-corrected panel-based sequencing (MyeloSeq-HD) at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable molecular MRD with DEC-C to determine if pre-emptive, MRD-guided therapy with DEC-C decreases relapse rates and improves progression-free survival.
Conditions
- Myelodysplastic Syndromes
Interventions
DEC-CDrug
* DEC-C will be provided by Taiho Pharmaceuticals. * Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant.
MyeloSeq-HDDevice
-Laboratory test developed at Washington University School of Medicine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with dose-limiting toxicities (Phase I only)Time frame: Completion of cycle 1 (each cycle is 28 days) for all phase I participants (estimated to be 13 months)
- Maximum tolerated dose (MTD) (Phase I only)Time frame: Completion of cycle 1 (each cycle is 28 days) for all phase I participants (estimated to be 13 months)
- Recommended phase II dose (Phase I only)Time frame: Completion of cycle 1 (each cycle is 28 days) for all phase I participants (estimated to be 13 months)
- Progression-free survival (PFS) (Phase II recommended dose only)Time frame: 1 year post-transplant
- Rate of relapse (Phase II recommended dose only)Time frame: 1 year post-transplant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.